Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors

Código QR

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors

In recent years, immune checkpoint inhibitors (ICIs) have become the standard treatment option for tumors. With the widespread application of ICIs, immune-related adverse events (irAEs) have gradually attracted the attention of researchers. Owing to the characteristics of ICIs, irAEs can affect each...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xue-lin Zou, Wei-yong Chen, Guang-yan Zhang, Hua Ke, Qiu-hong Yang, Xiao-bo Li
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	immune checkpoint inhibitors (ICIs) incidence risk factors thromboembolism prognosis Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/6f643805f9cf4647b9fe532a3cf11118
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Identification and Validation of Immune-Related Gene for Predicting Prognosis and Therapeutic Response in Ovarian Cancer
por: Zhao-Cong Zhang, et al.
Publicado: (2021)

Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study
por: Mohammed Safi, et al.
Publicado: (2021)

Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
por: Linda Wu, et al.
Publicado: (2021)

Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer
por: Rui He, et al.
Publicado: (2021)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021)

Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Yunhai Li, et al.
Publicado: (2021)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Di Wang, et al.
Publicado: (2021)

Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Donggun Lee, et al.
Publicado: (2021)

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
por: Rosaria De Filippi, et al.
Publicado: (2021)

Identification of the Immune Cell Infiltration Landscape in Hepatocellular Carcinoma to Predict Prognosis and Guide Immunotherapy
por: Shiyan Yang, et al.
Publicado: (2021)

Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Xiuqiong Chen, et al.
Publicado: (2021)

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Pan Shen, et al.
Publicado: (2021)

Identification of a Pyroptosis-Related Gene Signature for Predicting Overall Survival and Response to Immunotherapy in Hepatocellular Carcinoma
por: Susu Zheng, et al.
Publicado: (2021)

Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients
por: Thomas Bartl, et al.
Publicado: (2021)

Cardiac MRI in Immune Checkpoint Inhibitor Associated Pericarditis
por: Can Öztürk, et al.
Publicado: (2021)

Diagnostic and Prognostic Value of Immune/Inflammation Biomarkers for Venous Thromboembolism: Is It Reliable for Clinical Practice?
por: Xue J, et al.
Publicado: (2021)

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
por: Zoe Apalla, et al.
Publicado: (2021)

Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
por: Marina A. Lyadova, et al.
Publicado: (2021)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Nicola Personeni, et al.
Publicado: (2021)

GDPLichi: a DNA Damage Repair-Related Gene Classifier for Predicting Lung Adenocarcinoma Immune Checkpoint Inhibitors Response
por: Yang Leng, et al.
Publicado: (2021)

Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
por: Qi J, et al.
Publicado: (2021)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
por: Zou W, et al.
Publicado: (2021)

Novel Tumor-Specific Antigens for Immunotherapy Identified From Multi-omics Profiling in Thymic Carcinomas
por: Wentao Fang, et al.
Publicado: (2021)

Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis
por: Nuttapong Ngamphaiboon, et al.
Publicado: (2021)

Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events
por: Rilan Bai, et al.
Publicado: (2021)

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Anwen Xiong, et al.
Publicado: (2021)

Progress of Immune Checkpoint Inhibitors  in the Treatment of Advanced Pulmonary Neuroendocrine Tumors
por: Haoqing CHEN, et al.
Publicado: (2021)

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
por: Chengming Liu, et al.
Publicado: (2021)

A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
por: Yi-Dan Yan, et al.
Publicado: (2021)

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
por: Sara Elena Rebuzzi, et al.
Publicado: (2021)

Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
por: ZHU Kuikui, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in the Large Arteries of Lymphoma Patients under 50 Years of Age
por: Raffaella Calabretta, et al.
Publicado: (2021)

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
por: Kennedy Yao Yi Ng, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers
por: Brian W. Labadie, et al.
Publicado: (2021)

Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma
por: Shuo Hong, et al.
Publicado: (2021)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Xiaoyin Bai, et al.
Publicado: (2021)

Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan
por: Hisanaga K, et al.
Publicado: (2021)

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Shinsuke Suzuki, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio
por: Alberto Bongiovanni, et al.
Publicado: (2021)

Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan [Corrigendum]
por: Hisanaga K, et al.
Publicado: (2021)